Substituted anilines as CCR(4) antagonists

Patent metadata

Field	Value
Publication number	US-9567323-B2
Application number	US-201414452341-A
Country	US
Kind code	B2
Filing date	Aug 5, 2014
Priority date	Dec 1, 2011
Publication date	Feb 14, 2017
Grant date	Feb 14, 2017

Abstract

Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

First claim

What is claimed is:

1. A pharmaceutically acceptable salt of a compound having formula (Ie):

wherein
the dashed bond is a single or double bond;
R 1 is a member selected from the group consisting of hydrogen, C 1-8 alkyl, C 1-8 haloalkyl, C 1-8 hydroxyalkyl, C 3-8 , cycloalkyl, halogen, —CN, —SO 2 Me and —C(O)NH 2 ;
each R 2 is a member selected from the group consisting of C 1-8 alkyl, C 1-8 haloalkyl, halogen, —CN and C 1-8 alkoxy;
R 4 is a member selected from the group consisting of hydrogen, C 1-8 alkyl, C 1-8 haloalkyl and C 1-8 hydroxyalkyl;
the subscript n is an integer from 0 to 3;
Q is a member selected from the group consisting of C and N;
Y and Z are independently selected from the group consisting of CH and N;
R 6 is selected from the group consisting of H, —OH, C 1-8 alkyl, C 1-8 hydroxyalkyl, C 1-4 alkoxy-C 1-4 alkyl, —C(O)NR a R b , C 1-8 alkylene-C(O)NR a R b , —NH—C 1-4 alkylene-C(O)NR a R b , —C(O)—C 1-4 alkylene-NR a R b , —CO 2 H, C 1-8 alkylene-CO 2 H, —N(R a )C(O)NR a R b , C 1-8 alkylene N(R a )C(O)NR a R b , —NR a R b , C 1-8 alkylene-NR a R b , C 1-8 alkoxy, —C(O)OR a , C 1-8 alkylene-C(O)OR a , —CN, —C(O)R a , —SO 2 R a and —N(R a )C(O)R b ;
wherein
each R a and R b are independently selected from the group consisting of hydrogen, C 1-8 alkyl, C 1-8 hydroxyalkyl, C 1-8 haloalkyl, and C 1-8 alkoxy; and

R 7 is absent or is selected from the group consisting of H, C 1-8 alkyl and C 1-8 haloalkyl.

2. A pharmaceutically acceptable salt of claim 1 , wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidine and piperidine.

3. A pharmaceutically acceptable salt of claim 1 , wherein each R 2 is a member independently selected from the group consisting of C 1-8 alkyl, C 1-8 haloalkyl, halogen and —CN.

4. A pharmaceutically acceptable salt of claim 1 , wherein each R 2 is a member selected from the group consisting of C 1-8 alkyl, C 1-8 haloalkyl, halogen and —CN; and the subscript n is 0 or 1.

5. A pharmaceutically acceptable salt of claim 4 , wherein n is 1, and R 4 is hydrogen or methyl.

6. A pharmaceutically acceptable salt of claim 1 , wherein said compound is selected from the group consisting of:

7. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a pharmaceutically acceptable salt of claim 1 .

8. A pharmaceutical composition in accordance with claim 7 , comprising a pharmaceutically acceptable excipient and a pharmaceutically acceptable salt of a compound selected from the group consisting of:

9. A pharmaceutically acceptable salt of a compound having the formula:

Assignees

• Chemocentryx Inc

Inventors

• Charvat Trevor T
• Fan Junfa
• Lange Christopher W
• Leleti Manmohan Reddy
• Li Yandong
• Mali Venkat Reddy
• Mcmahon Jeffrey P
• Powers Jay
• Punna Sreenivas
• Yang Ju

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title